1. Home
  2. TOI vs MYGN Comparison

TOI vs MYGN Comparison

Compare TOI & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Oncology Institute Inc.

TOI

The Oncology Institute Inc.

HOLD

Current Price

$5.28

Market Cap

512.9M

Sector

Health Care

ML Signal

HOLD

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

HOLD

Current Price

$4.55

Market Cap

444.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TOI
MYGN
Founded
2007
1991
Country
United States
United States
Employees
641
N/A
Industry
Medical/Nursing Services
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
512.9M
444.2M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
TOI
MYGN
Price
$5.28
$4.55
Analyst Decision
Strong Buy
Buy
Analyst Count
3
7
Target Price
$6.67
$7.64
AVG Volume (30 Days)
1.8M
1.4M
Earning Date
05-07-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$771,400,000.00
Revenue This Year
$30.15
$6.86
Revenue Next Year
$25.77
$5.45
P/E Ratio
N/A
N/A
Revenue Growth
N/A
2.33
52 Week Low
$2.02
$3.53
52 Week High
$5.58
$8.59

Technical Indicators

Market Signals
Indicator
TOI
MYGN
Relative Strength Index (RSI) 64.36 54.92
Support Level $2.91 $4.31
Resistance Level $5.58 $4.92
Average True Range (ATR) 0.40 0.30
MACD 0.01 0.02
Stochastic Oscillator 77.49 67.30

Price Performance

Historical Comparison
TOI
MYGN

About TOI The Oncology Institute Inc.

The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

Share on Social Networks: